BRAF and metastatic melanoma: In metastatic malignant melanoma, which harbors BRAF V600E in 35–41% of cases,2, 3 treatment with the small-molecular BRAF V600E inhibitor vemurafenib has resulted in improved overall survival (OS) in a phase III clinical trial,4 although the long-term benefit was limited by the rapid acquisition of resistance.